...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of psychiatric practice. >CNS drug development: part III: future directions.
【24h】

CNS drug development: part III: future directions.

机译：中枢神经系统药物开发：第三部分：未来方向。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This column, the third in a series on central nervous system (CNS) drug development, discusses advances during the first decade of the 21st century and directions the field may take in the next 10 years. By identifying many possible new drug targets, the human genome project has created the potential to develop novel central nervous system (CNS) drugs with new mechanisms of action. At the same time, this proliferation of possible new targets has complicated the drug development process, since research has not yet provided guidance as to which targets may be most fruitful. This and other factors (eg, increasing regulatory requirements) have increased the cost and complexity of the drug development process. In addition, as more is learned about the biology of psychiatric illnesses, syndromes may be subdivided into more specific entities that are better understood from a pathophysiological and pathoetiological perspective. This is likely to lead to development of more targeted treatments focused on underlying causes of illness as well as prevention. The development of drugs for Alzheimer's disease is discussed as a possible model for future CNS drug development. We are at the beginning of an era when it is likely that the way in which CNS drugs are developed will need to be rethought, which will call for flexibility and creativity on the part of both drug developers and clinical researchers.
机译：本专栏文章是中枢神经系统（CNS）药物开发系列文章中的第三篇，讨论了21世纪前十年的发展以及该领域在未来十年中可能采取的方向。通过确定许多可能的新药物靶标，人类基因组计划创造了开发具有新作用机制的新型中枢神经系统（CNS）药物的潜力。同时，可能的新靶标的激增使药物开发过程复杂化，因为尚未就哪些靶标可能最有成果的研究提供指导。该因素和其他因素（例如，越来越多的法规要求）增加了药物开发过程的成本和复杂性。另外，随着对精神疾病生物学的更多了解，可以将综合症细分为更具体的实体，从病理生理学和病理学的角度可以更好地理解这些实体。这可能会导致针对疾病的根本原因和预防的针对性治疗的发展。讨论了用于阿尔茨海默氏病的药物开发，作为未来中枢神经系统药物开发的可能模型。我们正处于一个时代的开始，有可能需要重新考虑CNS药物的开发方式，这将要求药物开发商和临床研究人员都具有灵活性和创造力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号